Enorama Pharma AB (SE:ERMA)
:ERMA
Want to see SE:ERMA full AI Analyst Report?
ERMA Stock Chart & Stats
kr1.91
-kr0.30(-12.50%)
At close: 4:00 PM EST
kr1.91
-kr0.30(-12.50%)
Day’s Range― - ―
52-Week Rangekr0.21 - kr3.58
Previous CloseN/A
Volume29.79K
Average Volume (3M)4.35K
Market Cap
kr27.15M
Enterprise Valuekr9.31M
Total Cash (Recent Filing)kr17.76M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta0.68
Next Earnings
Aug 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.91
Shares Outstanding74,588,684
10 Day Avg. Volume2,975
30 Day Avg. Volume4,348
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)-5.66
Price to Sales (P/S)48.45
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Near-zero DebtNear-zero debt reduces immediate insolvency risk and interest burden, giving Enorama flexibility to pursue development or partner deals without heavy fixed financing costs. Over 2–6 months this structural low leverage supports runway extension choices despite other funding needs.
Partnering/licensing Business ModelEnorama’s focus on licensing, milestone and royalty monetization lowers capital intensity versus building a direct commercial organization. Structurally this model enables scalable revenue upside via partners, limits fixed costs, and aligns incentives with larger commercial partners over the medium term.
Demonstrated Positive Gross Profit (2024)Achieving positive gross profit in 2024 indicates underlying product economics can be viable once scale or cost structure improves. This provides durable evidence that formulations can be commercially competitive and attractive to partners if revenue and cost control are restored.
Bears Say
Negative Shareholders' EquityNegative equity reflects accumulated losses that erode the capital base and limit financing flexibility. Over the next several months this structural weakness raises the likelihood of dilutive funding, creditor constraints, or restructuring, weakening negotiating power with partners and investors.
Persistent Cash BurnSustained negative operating and free cash flow indicates ongoing cash burn that requires repeated external funding or partner advance payments. This structural cash deficit pressures management priorities, increases dilution risk, and constrains sustained R&D or commercialization activities over months.
Very Small, Declining Revenue And MarginsA tiny, shrinking revenue base with worsening margins undermines scale economics and partner leverage. Structurally this reduces internal funding capacity, weakens commercialization credibility, and makes it harder to demonstrate sustainable unit economics required for long-term partner-led commercialization.
ERMA FAQ
What was Enorama Pharma AB’s price range in the past 12 months?
Enorama Pharma AB lowest stock price was kr0.21 and its highest was kr3.58 in the past 12 months.
What is Enorama Pharma AB’s market cap?
Enorama Pharma AB’s market cap is kr27.15M.
When is Enorama Pharma AB’s upcoming earnings report date?
Enorama Pharma AB’s upcoming earnings report date is Aug 26, 2026 which is in 73 days.
How were Enorama Pharma AB’s earnings last quarter?
Enorama Pharma AB released its earnings results on May 20, 2026. The company reported -kr0.17 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.17.
Is Enorama Pharma AB overvalued?
According to Wall Street analysts Enorama Pharma AB’s price is currently Overvalued.
Does Enorama Pharma AB pay dividends?
Enorama Pharma AB does not currently pay dividends.
What is Enorama Pharma AB’s EPS estimate?
Enorama Pharma AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Enorama Pharma AB have?
Enorama Pharma AB has 74,588,684 shares outstanding.
What happened to Enorama Pharma AB’s price movement after its last earnings report?
Enorama Pharma AB reported an EPS of -kr0.17 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 23.333%.
Which hedge fund is a major shareholder of Enorama Pharma AB?
Currently, no hedge funds are holding shares in SE:ERMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Enorama Pharma AB
Enorama Pharma AB (publ) is a Swedish pharmaceutical enterprise primarily engaged in the creation, production, and distribution of specialized chewing gums. These products are formulated with established generic active ingredients. The company's offerings encompass nicotine chewing gum, designed to aid individuals in quitting smoking, as well as medical cannabis chewing gums. The cannabis-based gums are intended for a variety of applications, including non-pharmaceutical uses, along with therapeutic purposes such as targeted drug delivery through the oral lining and the treatment of allergic rhinitis. This firm operates out of its headquarters in Malmö, Sweden.